Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
<a href="http://www.senate.gov/lobby">http://www.senate.gov/lobby</a>

# **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employe CVS Health (and subsidiaries)	d Individual
2. Address Address 1275 Pennsylvania Avenue, NW	Address2 Suite 700
City Washington State	$\underline{\text{DC}}$ Zip Code $\underline{20004}$ Country $\underline{\text{USA}}$
3. Principal place of business (if different than line 2)	
City Woonsocket State	<u>RI</u> Zip Code <u>02895</u> Country <u>USA</u>
4a. Contact Name b. Telephone N  Mrs. Shannon Penberthy 2027723504	umber c. E-mail shannon.penberthy@cvshealth.com  5. Senate ID# 302778-12
7. Client Name Self Check if client is a state  CVS Health (and subsidiaries)	or local government or instrumentality 6. House ID# 394420000
9. Check if this filing amends a previously filed version of this report  10. Check if this is a Termination Report  Termination	
	MUST complete either Line 12 or Line 13
12. Lobbying INCOME relating to lobbying activities for this reporting period was:	13. Organizations  EXPENSE relating to lobbying activities for this reporting period were:
<u>Less than \$5,000</u>	<u>Less than \$5,000</u>
\$5,000 or more \$	\$5,000 or more \$ 3,210,000.00
Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
	Method A. Reporting amounts using LDA definitions only
	Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
	Method C. Reporting amounts under section 162(e) of the Internal Revenue Code
Signature Digitally Signed By: Shannon Penberthy	Date 4/22/2024 5:37:14 PM

15. General issue area code PHA

16	×-	pecific	ın	hh	57113	ന 1	CCIL	20
10.	O	DCCIIIC	w	$\nu \nu$	٧ш	<b>~</b> 1	.oou	U.J

Issues related to drug p	ricing transparency, women's healt	h, and COVID-19 testing,	vaccination and treatment.	
	ole Community Access to Pharmac Community Access to Pharmacist			
17. House(s) of Congre	ess and Federal agencies Check	c if None		
U.S. SENATE, U.S. HO	OUSE OF REPRESENTATIVES, I	Health & Human Services	- Dept of (HHS), White House Office	
18. Name of each indiv	idual who acted as a lobbyist in thi	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			
Amy	Rosenbaum			
Joy	McGlaun			
Kaitlyn	Lane			
Yujin	Lee			
Rob	Butora			
Robert	Warbinton			
19. Interest of each fore	eign entity in the specific issues list	ed on line 16 above	Check if None	

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code TAX 16. Specific lobbying issues Issues related to the corporate tax rate. 17. House(s) of Congress and Federal agencies Check if None U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES 18. Name of each individual who acted as a lobbyist in this issue area First Name Last Name Suffix Covered Official Position (if applicable) New Shannon Penberthy 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

- 15. General issue area code MMM
- 16. Specific lobbying issues

	are Part D, Medicare Advantage, M d to Accountable Care Organization		nd telehealth. Issues related to COVID testing, vaccing are Shared Savings Program.	nation, and
S. 1967 – Patients Befo S. 2973 - Modernizing S. 3430 - Better Mental H.R. 2679 – Pharmacy H.R. 3285 – Fairness fo H.R. 1613 – Drug Price H.R. 3561 – Promoting H.R. 5378 - Lower Cos	nefit Manager Reform Act of 2023 re Middlemen Act of 2023 and Ensuring PBM Accountability (Health Care, Lower-Cost Drugs, and Benefit Manager Accountability Actor Patient Medications Actor Transparency in Medicaid Act of 2 Access to Treatments and Increasints, More Transparency Act Patients Against PBM Abuses Act	nd Extenders Act t of 2023	nsparency Act of 2023	
17. House(s) of Congre	ss and Federal agencies Check	if None		
U.S. SENATE, U.S. HO Medicaid Services (CM		ealth & Human Services	- Dept of (HHS), White House Office, Centers For M	Medicare and
·	idual who acted as a lobbyist in this	issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Rosenbaum		Colored Chicken Louisian (in approachs)	
Joy	McGlaun			
Kaitlyn	Lane			
Shannon	Penberthy			
Rob	Butora			
Yujin	Lee			
Robert	Warbinton			
Melissa	Schulman			
Nicole	Burda			
10 Interest of each force	ion antituin the analific issues lists	d on line 16 shave	Shoot if None	
19. Interest of each fore	ign entity in the specific issues liste	d on the 16 above	DIECK II INOIC	

15. General issue area c	ode INS			
16. Specific lobbying is	sues			
Issues related to employ	yer, small group and individual insu	rance markets.		
H.R. 6283 – Delinking	Revenue from Unfair Gouging Act			
17. House(s) of Congre	ss and Federal agencies Check	if None		
U.S. SENATE, U.S. HO	OUSE OF REPRESENTATIVES			
18. Name of each indiv	idual who acted as a lobbyist in this	issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Joy	McGlaun			
Yujin	Lee			
Kaitlyn	Lane			
Shannon	Penberthy			
Robert	Warbinton			
Robert	Butora			
Amy	Rosenbaum			
19. Interest of each fore	ign entity in the specific issues liste	d on line 16 above	Check if None	

	•	•	issue areas in which the registrant engaged in lobbying the information as requested. Add additional page(s) a	-
15. General issue area code	LBR			
16. Specific lobbying issues				
Issues related to the competi	itive nature of the pharmacy be	enefit manager industry ar	nd workforce issues.	
17. House(s) of Congress an	nd Federal agencies Check	if None		
U.S. SENATE, U.S. HOUSI	E OF REPRESENTATIVES, H	lealth & Human Services	- Dept of (HHS), White House Office	
18. Name of each individual	I who acted as a lobbyist in this	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			
Amy	Rosenbaum			
Joy	McGlaun			
Yujin	Lee			
Rob	Butora			
Robert	Warbinton			
Kaitlyn	Lane			
Melissa	Schulman			

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf

of the client during the r	reporting period. Using a separ	rate page for each code, provide i	nformation as requested. Add add	litional page(s) as needed.
15. General issue area co	ode CSP			
16. Specific lobbying iss	sues			
Issues related to organiz	zed retail crime and consumer	safety.		
17. House(s) of Congres	ss and Federal agencies C	Check if None		
U.S. SENATE, U.S. HC	OUSE OF REPRESENTATIVE	ES		
18. Name of each indivi	dual who acted as a lobbyist is	n this issue area		
First Name	Last Name	Suffix	Covered Official Position (if a	applicable) New
Shannon	Penberthy			
Robert	Warbinton			
Joy	McGlaun			
	age - Complete ONLY where	e registration information has cl	hanged.	
20. Client new address				
Address				
City		State	Zip Code	Country
21. Client new principal	place of business (if different	t than line 20)		
City		State	Zip Code	Country
22. New General descrip	ption of client's business or ac	tivities		
LOBBYIST UPD 23. Name of each previous		is no longer expected to act as a l	lobbyist for the client	
First Name	Last Name	Suffix First Na	ame Last Name	Suffix
1		3		
2		4		
ISSUE UPDATE 24. General lobbying iss	sue that no longer pertains			

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name			Principal Place of Bu (city and state or cou				
					City State	Countr	у
26. Name of each previously reported	l organization that is no long	er affiliat	ed with the regis	strant or client			
1	2			3			
FOREIGN ENTITIES							
27. Add the following foreign entities	s: 						
Name	Address Street Address City State/Province	Country		place of busine state or country		Amount of contribution for lobbying activities	Ownership percentage in client
			City State	Country			%
28. Name of each previously reported	I foreign entity that no longe	er owns, or	r controls, or is	affiliated with	the regi	strant, client or affiliate	ed organization
1 2	<u>3</u>			5	, ,		_
CONVICTIONS DISCLO	SURE						
29. Have any of the lobbyists listed of an illegal kickback, tax evasion, fraucon No Yes							mbezzlement,
Lobbyist Name				Description of 0	Offense	(s)	

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby

## **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employ  CVS Health (and subsidiaries)	ed Individual				
2. Address					
Address1 1275 Pennsylvania Avenue, NW	Address2 Suite 700				
City Washington Stat	2 DC Zip Code 20004	Country USA			
	<u> </u>				
3. Principal place of business (if different than line 2)	7. 7. 7. A. 1. 02002				
City Woonsocket Stat	2 RI Zip Code 02895	Country USA			
1.71					
<u>-</u>	Number c. E-mail	5. Senate ID#			
Mrs. Shannon Penberthy 2027723504	shannon.penberthy@cvshealth.com	302778-12			
7. Client Name Self Check if client is a state	e or local government or instrumentality	6 House ID#			
CVS Health (and subsidiaries)	,	6. House ID# 394420000			
1	Date 11. No Lobbying Issue	-			
INCOME OR EXPENSES - VO	U MUST complete either Line 12 or Line 1	12			
12. Lobbying	13. Organizations				
<b>INCOME</b> relating to lobbying activities for this reporting period was:	<b>EXPENSE</b> relating to lobbying activities for this re	porting period were:			
<u>Less than \$5,000</u>	<u>Less than \$5,000</u>				
\$5,000 or more \$	\$5,000 or more \$ 2,470,000.00				
Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).  14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.  Method A. Reporting amounts using LDA definitions only  Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code					
	Method C. Reporting amounts under section 16 Revenue Code	2(e) of the Internal			

https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2

- 15. General issue area code PHA
- 16. Specific lobbying issues

H.R. 1770. The Equita	ble Community Access to Pharmaci	st Services Act		
	Community Access to Pharmacist			
17. House(s) of Congre	ess and Federal agencies   Check	if None		
U.S. SENATE, U.S. H	OUSE OF REPRESENTATIVES, H	Iealth & Human Services	- Dept of (HHS), White House Office	
18. Name of each indiv	ridual who acted as a lobbyist in this	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			
Amy	Rosenbaum			
	Н			
Joy	McGlaun			
	McGlaun  Lane			
Joy Kaitlyn Yujin				
Kaitlyn	Lane			

	•		ssue areas in which the registrant engaged in lobbyir e information as requested. Add additional page(s) a	_
15. General issue area co	ode TAX			
16. Specific lobbying iss	ues			
Issues related to the corp	oorate tax rate.			
17. House(s) of Congres	s and Federal agencies Check	if None		
U.S. SENATE, U.S. HO	USE OF REPRESENTATIVES			
18. Name of each individ	dual who acted as a lobbyist in this	issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			
Melissa	Schulman			
19. Interest of each forei	gn entity in the specific issues liste	ed on line 16 above	Check if None	2.5

- 15. General issue area code MMM
- 16. Specific lobbying issues

	e Part D, Medicare Advantage, M to Accountable Care Organization		nd telehealth. Issues related to COVID testing, vaccing care Shared Savings Program.	ation, and
S. 1967 – Patients Before S. 2973 - Modernizing an S. 3430 - Better Mental H H.R. 2679 – Pharmacy Be H.R. 3285 – Fairness for H.R. 1613 – Drug Price T H.R. 3561 – Promoting A H.R. 5378 - Lower Costs,	d Ensuring PBM Accountability of Health Care, Lower-Cost Drugs, a senefit Manager Accountability Ac Patient Medications Act Cransparency in Medicaid Act of access to Treatments and Increasing	nd Extenders Act et of 2023	nsparency Act of 2023	
17 House(s) of Congress	and Federal agencies Check	if None		
Medicaid Services (CMS)			- Dept of (HHS), White House Office, Centers For N	Medicare and
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Rosenbaum			
Joy	McGlaun			
Kaitlyn	Lane			
Shannon	Penberthy			
Rob	Butora			
Yujin	Lee			
Robert	Warbinton			
Melissa	Schulman			
Nicole	Burda			
19. Interest of each foreig	n entity in the specific issues liste	ed on line 16 above	Check if None	

15. General issue area code INS

16. Specific lobbying i	ssues			
Issues related to emplo	yer, small group and individual insu	rance markets.		
S. 1542/H.R. 6283 - D	elinking Revenue from Unfair Goug	ing Act		
17. House(s) of Congre	ess and Federal agencies Check	if None		
U.S. SENATE, U.S. H	OUSE OF REPRESENTATIVES			
18. Name of each indiv	vidual who acted as a lobbyist in this	issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Joy	McGlaun			
Yujin	Lee			
Kaitlyn	Lane			
Shannon	Penberthy			
Robert	Warbinton			
Robert	Butora			
Amy	Rosenbaum			
Melissa	Schulman			
19. Interest of each for	eign entity in the specific issues liste	ed on line 16 above	Check if None	-

			ssue areas in which the registrant engaged in lobbying in loboration as requested. Add additional page(s) as	
15. General issue area co	ode LBR			
16. Specific lobbying iss	sues			
Issues related to the con	petitive nature of the pharmacy be	nefit manager industry a	nd workforce issues.	9.4
17. House(s) of Congres	s and Federal agencies Check	if None		
U.S. SENATE, U.S. HO	USE OF REPRESENTATIVES, H	ealth & Human Services	- Dept of (HHS), White House Office	- 3
18. Name of each indivi-	dual who acted as a lobbyist in this	issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			
Amy	Rosenbaum			
Joy	McGlaun			
Yujin	Lee			
Rob	Butora			
Robert	Warbinton			
Kaitlyn	Lane			
Melissa	Schulman			

Robert	Warbinton			
Kaitlyn	Lane			
Melissa	Schulman			
19. Interest of each foreign entity	in the specific issues listed on line 1	6 above	Check if None	
				7

						he registrant engaged in luested. Add additional pa	
15. General issue area	code CSP						
16. Specific lobbying	issues						
Issues related to organ	nized retail crime and c	onsumer safety.					
17. House(s) of Congr	ress and Federal agence	es Check if No	one				
U.S. SENATE, U.S. H	OUSE OF REPRESE	NTATIVES					)]
18. Name of each indi	vidual who acted as a	lobbyist in this issue	area				
First Name	Last Nan	ne	Suffix	I	Covered Office	cial Position (if applicable	e) New
Shannon	Penberth	у				·	
Robert	Warbinto	n					
19. Interest of each for	noi om omtitu im the amee	ifia issues listed on	lima 16 albayya	Charle	f None		
19. Interest of each for	reign entity in the spec	inc issues listed on	ine to above	Check i	ii None		
Information Update	Page - Complete ONI	LY where registrati	on informat	ion has chan	ged.		
20. Client new address	5						
Address							
City				State	Zi	p Code	Country
21. Client new princip	al place of business (if	different than line	20)				
City				State	7	p Code	Country
						p code	
22. New General description	ription of client's busin	ness or activities					
LOBBYIST UP	DATE						
23. Name of each prev	viously reported indivi	dual who is no longe	er expected to	act as a lobb	yist for the cli	ent	
4							
First Name	Last Name		Suffix	First Name	;	Last Name	Suffix
ISSUE UPDAT	E						
24. General lobbying i	issue that no longer per	rtains					
AFFILIATED (	ORGANIZATIO	ONS					
25. Add the following	affiliated organization	(s)					
Internet Address:	-						
			Addre	ess		<u> </u>	
Na	nme	Street Address	, iddic			Principal Place	
- 1.0		City	State/Prov	ince Zip	Country	(city and state	or country)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FC	REI	GN	ENT	ITIES
----	-----	----	-----	-------

27. Add the following foreign entities:

Name	Address Street Address City State/Province	Country	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
------	--	---------	---	--	--------------------------------------

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

#### **CONVICTIONS DISCLOSURE**

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlemen
an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No Yes

Lobbyist Name	Description of Offense(s)

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby

## **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed CVS Health (and subsidiaries)	l Individual				
2. Address Address1 1275 Pennsylvania Avenue, NW	Address2 Suite 700				
City Washington State					
3. Principal place of business (if different than line 2)  City Woonsocket State	RI Zip Code 02895 Country USA				
ony <u>monatore</u>	III 21p code v2055 County County				
4a. Contact Name b. Telephone N Mrs. Shannon Penberthy 2027723504	umber c. E-mail shannon.penberthy@cvshealth.com  5. Senate ID# 302778-12				
	or local government or instrumentality 6. House ID# 394420000				
9. Check if this filing amends a previously filed version of this report  10. Check if this is a Termination Report  Termination					
	MUST complete either Line 12 or Line 13				
12. Lobbying INCOME relating to lobbying activities for this reporting period was:	13. Organizations  EXPENSE relating to lobbying activities for this reporting period were:				
Less than \$5,000	Less than \$5,000				
\$5,000 or more \$	\$5,000 or more \$ 1,520,000.00				
Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).  14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.					
	Method A. Reporting amounts using LDA definitions only				
	Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code				
	Method C. Reporting amounts under section 162(e) of the Internal Revenue Code				
Signature Digitally Signed By: Shannon Penberthy	Date 10/21/2024 5:58:25 PM				

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

	cific		

Issues related to retail	pharmacy, drug pricing, and women	n's health.		
1 -	ble Community Access to Pharmac Community Access to Pharmacist			
17. House(s) of Congre	ess and Federal agencies  Check	x if None		
U.S. SENATE, U.S. H	OUSE OF REPRESENTATIVES, I	Health & Human Servic	ees - Dept of (HHS), White House Office	
18. Name of each indiv	ridual who acted as a lobbyist in thi	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			
Amy	Rosenbaum			
Joy	McGlaun			
Kaitlyn	Lane			
Yujin	Lee			
Rob	Butora			
Robert	Warbinton			
19. Interest of each for	eign entity in the specific issues list	ed on line 16 above	Check if None	

of the client during the re	eporting period. Using a separate p	page for each code, provide	de information as requested. Add additional page(s) a	s needed.
15. General issue area co	ode TAX			
16. Specific lobbying iss	ues			
Issues related to the corp	orate tax rate.			
17. House(s) of Congress	s and Federal agencies Check	if None		
U.S. SENATE, U.S. HO	USE OF REPRESENTATIVES			
18. Name of each individ	dual who acted as a lobbyist in this	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			
Melissa	Schulman			
19. Interest of each foreign	gn entity in the specific issues liste	ed on line 16 above	Check if None	•

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf

- 15. General issue area code MMM
- 16. Specific lobbying issues

	e Part D, Medicare Advantage, Moto Accountable Care Organization		nd telehealth. Issues related to COVID testing, vaccing care Shared Savings Program.	ation, and
S. 1967 - Patients Before S. 2973 - Modernizing ar S. 3430 - Better Mental F H.R. 2679 - Pharmacy Be H.R. 3285 - Fairness for H.R. 1613 - Drug Price T H.R. 3561 - Promoting A H.R. 5378 - Lower Costs	nd Ensuring PBM Accountability (Health Care, Lower-Cost Drugs, and enefit Manager Accountability Acceptationt Medications Acter ansparency in Medicaid Act of 2 access to Treatments and Increasing	nd Extenders Act t of 2023	nsparency Act of 2023	
17. House(s) of Congress	and Federal agencies	if None		
U.S. SENATE, U.S. HOU Medicaid Services (CMS		ealth & Human Services	- Dept of (HHS), White House Office, Centers For M	1edicare and
18. Name of each individ	ual who acted as a lobbyist in this	issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Rosenbaum			
Joy	McGlaun			
Kaitlyn	Lane			
Shannon	Penberthy			
Rob	Butora			
Yujin	Lee			
Robert	Warbinton			
Melissa	Schulman			
Nicole	Burda			
19. Interest of each foreig	n entity in the specific issues liste	ed on line 16 above	Check if None	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code INS 16. Specific lobbying issues Issues related to employer, small group and individual insurance markets. S. 1542/H.R. 6283 - Delinking Revenue from Unfair Gouging Act 17. House(s) of Congress and Federal agencies Check if None U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES 18. Name of each individual who acted as a lobbyist in this issue area Suffix First Name Last Name Covered Official Position (if applicable) New Joy McGlaun Yujin Lee Kaitlyn Lane Shannon Penberthy Robert Warbinton Robert Butora Amy Rosenbaum Melissa Schulman

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf

of the client during the	reporting period. Using a separate pa	age for each code, provi-	de information as requested. Add additional page(s) as	s needed.
15. General issue area	code LBR			
16. Specific lobbying i	ssues			
Issues related to the co	empetitive nature of the pharmacy ber	nefit manager industry a	nd workforce issues.	
17. House(s) of Congre	ess and Federal agencies Check	if None		
U.S. SENATE, U.S. H	OUSE OF REPRESENTATIVES, He	ealth & Human Services	- Dept of (HHS), White House Office	9 /
18. Name of each indiv	vidual who acted as a lobbyist in this	issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			
Amy	Rosenbaum			
Joy	McGlaun			
Yujin	Lee			
Rob	Butora			
Robert	Warbinton			
Kaitlyn	Lane			
Melissa	Schulman			
19. Interest of each for	eign entity in the specific issues listed	d on line 16 above	Check if None	

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf

15. General issue area o	code CSP			
16. Specific lobbying is	ssues			
Issues related to organi	zed retail crime and consumer sa	fety.		
17.11. ( ) 60		1 '627		
	ess and Federal agencies Che			
	OUSE OF REPRESENTATIVES			
18. Name of each indiv	idual who acted as a lobbyist in t	this issue area		
First Name	Last Name	Suffix	Covered Official Position (i	if applicable) New
Shannon	Penberthy			
Robert	Warbinton			
19. Interest of each fore	eign entity in the specific issues l	isted on line 16 above C	Check if None	
				11
Information Update P	age - Complete ONLY where r	egistration information has	s changed.	
20. Client new address			9	
Address				
			Zip Code	Country
	l place of business (if different th	_		
			Zin Codo	Country
•			Zip Code	Country
22. New General descri	iption of client's business or activ	vities		
	) ATE			
LOBBYIST UPI	JAIL			
23. Name of each previ	ously reported individual who is	no longer expected to act as	a lobbyist for the client	
First Name	Last Name	Suffix First	Name Last Name	Suffix
1		3		
_				
2		4		
ICCLIE LIDD ATRE	1			
ISSUE UPDATE				
24. General lobbying is	sue that no longer pertains			

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

#### **AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

LD-2 Disclosure Form

Description of Offense(s)

		A 1.1	1				
Name	Street Address City	Add State/Pro		Country		Principal Place of Bu (city and state or con	
					City State	Countr	у
26. Name of each previously repo	orted organization that is no long	er affiliate	ed with the regi	strant or client			
1	2			3			
FOREIGN ENTITIES  27. Add the following foreign en	tities:						
Name	Address Street Address City State/Province	Country		place of busine state or countr		Amount of contribution for lobbying activities	Ownership percentage in client
			City State	Country			%
28. Name of each previously repo	orted foreign entity that no longer	r owns, or	controls, or is	affiliated with	the regi	strant, client or affiliate	ed organization
1 2	3 4			<b>5</b>			
CONVICTIONS DISC	LOSURE						

Lobbyist Name

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby

# **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employe CVS Health (and subsidiaries)	d Individual			
2. Address Address1 1275 Pennsylvania Avenue, NW	Address2 Suite 700			
City Washington State	<u>DC</u> Zip Code <u>20004</u>	Country <u>USA</u>		
3. Principal place of business (if different than line 2)				
City Woonsocket State	<u>RI</u> Zip Code <u>02895</u>	Country USA		
4a. Contact Name b. Telephone No. Mrs. Shannon Penberthy 2027723504	umber c. E-mail shannon.penberthy@cvshealth.com	5. Senate ID# 302778-12		
7. Client Name Self Check if client is a state CVS Health (and subsidiaries)	or local government or instrumentality	6. House ID# 394420000		
9. Check if this filing amends a previously filed version of this report  10. Check if this is a Termination Report  Termination		•		
INCOME OR EXPENSES - YOU	MUST complete either Line 12 or Line 1	3		
12. Lobbying	13. Organizations			
INCOME relating to lobbying activities for this reporting period was:  Less than \$5,000	EXPENSE relating to lobbying activities for this relates than \$5,000	porting period were:		
\$5,000 or more \$	\$5,000 or more \$ 2,040,000.00			
Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).  14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.  Method A. Reporting amounts using LDA definitions only  Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  Method C. Reporting amounts under section 162(e) of the Internal Revenue Code				
Signature Digitally Signed By: Shannon Penherthy	Da			

- 15. General issue area code PHA
- 16. Specific lobbying issues

Issues related to retail pharmacy, drug pricing, and women's health.					
H.R. 1770, The Equitable Community Access to Pharmacist Services Act S. 2477, The Equitable Community Access to Pharmacist Services Act					
17. House(s) of Congr	ress and Federal agencies  Check	if None			
U.S. SENATE, U.S. H	IOUSE OF REPRESENTATIVES, H	lealth & Human Service	es - Dept of (HHS), White House Office		
18. Name of each indi-	vidual who acted as a lobbyist in this	s issue area			
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New	
Shannon	Penberthy				
Amy	Rosenbaum				
Joy	McGlaun				
Kaitlyn	Lane				
Yujin	Lee				
Rob	Butora				
Robert	Warbinton				
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None					

	•	_	ll issue areas in which the registrant engaged in lobbying ride information as requested. Add additional page(s) as n	•
15. General issue area code TAX	X			
16. Specific lobbying issues				
Issues related to the corporate to	ax rate.			
17. House(s) of Congress and F	ederal agencies Check if None			
U.S. SENATE, U.S. HOUSE O	F REPRESENTATIVES			16
18. Name of each individual wh	o acted as a lobbyist in this issue area	a		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			
Melissa	Schulman			
19. Interest of each foreign entit	y in the specific issues listed on line	16 above	Check if None	

- 15. General issue area code MMM
- 16. Specific lobbying issues

	e Part D, Medicare Advantage, M o Accountable Care Organization		nd telehealth. Issues related to COVID testing, vaccine care Shared Savings Program.	ation, and
S. 1967 – Patients Before S. 2973 - Modernizing an S. 3430 - Better Mental H H.R. 2679 – Pharmacy Bo H.R. 3285 – Fairness for I H.R. 1613 – Drug Price T H.R. 3561 – Promoting A H.R. 5378 - Lower Costs,	d Ensuring PBM Accountability (lealth Care, Lower-Cost Drugs, and enefit Manager Accountability Acceptationt Medications Acter (ransparency in Medicaid Act of access to Treatments and Increasing	nd Extenders Act ext of 2023	nsparency (PATIENT) Act of 2023	
17. House(s) of Congress		if None	Dest of (IIII) White House Office Control For N	( 1' 1
U.S. SENATE, U.S. HOU Medicaid Services (CMS)		lealth & Human Services	- Dept of (HHS), White House Office, Centers For M	1edicare and
· · ·	ual who acted as a lobbyist in this	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Rosenbaum	Sullx	Covered Official Position (it applicable)	Thew
Joy	McGlaun			
Kaitlyn	Lane			
Shannon	Penberthy			
Rob	Butora			
Yujin	Lee			
Robert	Warbinton			
Melissa	Schulman		-	
Nicole	Burda			
19. Interest of each foreig	n entity in the specific issues liste	ed on line 16 above	Check if None	

- 15. General issue area code INS
- 16. Specific lobbying issues

Issues related to employer si	mall group and individual ins	urance markets			
Issues related to employer, small group and individual insurance markets.  S. 1542/H.R. 6283 - Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 10455 - To direct the Secretary of Health and Human Services to establish the Health Sector Cybersecurity Coordination Center, and for other purposes. Issues related to pharmacy benefit managers.  H.R. 10545 - the American Relief Act, 2025. Issues related to pharmacy benefit managers.					
17. House(s) of Congress and	d Federal agencies Check	k if None			
U.S. SENATE, U.S. HOUSE	OF REPRESENTATIVES				
18. Name of each individual	who acted as a lobbyist in the	is issue area			
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New	
Joy	McGlaun				
Yujin	Lee				
Kaitlyn	Lane				
Shannon	Penberthy				
Robert	Warbinton				
Robert	Butora				
Amy	Rosenbaum				
Melissa	Schulman				
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None					

		-	issue areas in which the registrant engaged in lobbyir de information as requested. Add additional page(s) a	_
15. General issue area coo	de LBR			
16. Specific lobbying issu	nes			
Issues related to the comp	petitive nature of the pharmacy bo	enefit manager industry a	nd workforce issues.	
17. House(s) of Congress	and Federal agencies Check	if None		
U.S. SENATE, U.S. HOU	JSE OF REPRESENTATIVES, F	Iealth & Human Services	- Dept of (HHS), White House Office	- 11
18. Name of each individ	ual who acted as a lobbyist in this	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			
Amy	Rosenbaum			
Joy	McGlaun			
Yujin	Lee			
Rob	Butora			
Robert	Warbinton			
Kaitlyn	Lane			
Melissa	Schulman			

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf

of the client during the	e reporting period. Using a separate	page for each code, provid	le information as requested. Add addition	onal page(s) as needed.
15. General issue area	code CSP			
16. Specific lobbying	issues			
Issues related to organ	nized retail crime and consumer safe	ety.		
	ress and Federal agencies Chec	k if None		
U.S. SENATE, U.S. H	IOUSE OF REPRESENTATIVES			7
18. Name of each indi	vidual who acted as a lobbyist in th	is issue area		
First Name	Last Name	Suffix	Covered Official Position (if app	olicable) New
Shannon	Penberthy			
Robert	Warbinton			
19. Interest of each for	reign entity in the specific issues lis	sted on line 16 above C	Check if None	
				-
•	Page - Complete ONLY where re		s changed	
20. Client new address		Sisti ation miormation has	, changed.	
			7im Codo	Country
			Zip Code	Country
21. Client new princip	al place of business (if different that	in line 20)		
City		State _	Zip Code	Country
22. New General descri	ription of client's business or activi	ties		
LOBBYIST UP	DATE			
23. Name of each prev	viously reported individual who is r	no longer expected to act as	a lobbyist for the client	
First Name	Last Name	Suffix   First	Name Last Name	Suffix
1 Yujin	Lee	2		
ISSUE UPDAT	E			
24. General lobbying i	issue that no longer pertains			
	DC ANIZATIONS			
AFFILIAI ED (	ORGANIZATIONS			
25. Add the following	affiliated organization(s)			
Internet Address:				

21/25, 5:19 PM		LD2 Lobbying Disclosure Report					
Name	Street Ac	Address Street Address City State/Province Zip Country		Country	Principal Place of Business (city and state or country)		
26. Name of each previously reporte	ed organization that	t is no longer affilia	ted with the regi	istrant or client			
FOREIGN ENTITIES  27. Add the following foreign entition	es:						
Name Street Address		ddress Province Country	Principal place of business (city and state or country)		Amount of contribution for lobbying activities	Ownership percentage in client	
28. Name of each previously reported	ed foreign entity that	at no longer owns, o	or controls, or is	affiliated with the r	registrant, client or affiliat	ed organization	
CONVICTIONS DISCLO  29. Have any of the lobbyists listed an illegal kickback, tax evasion, fram No Yes	on this report been				•	embezzlement,	
Lobbyist Name		Description of Offense(s)					